Lymph node ratio risk classification in stage III colon cancer: A pooled analysis of 16,425 patients from the ACCENT database.

Comparison of innovative estimation of efficacy to standard using the ACCENT database.

Predictive and prognostic value of gender in early stage colon cancer: A pooled analysis of 33,345 patients from the ACCENT database.

The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum: NSABP R-04.

The efficacy of oxaliplatin when added to 5-fluorouracil/leucovorin in stage II colon cancer.

Overall survival and updated disease-free survival results of the NSABP C-08 trial assessing bevacizumab in stage II and III colon cancer.
**Saturday, June 4, 2011**

**2:00 p.m. - 6:00 p.m.**  
**Poster Discussion Session:**  
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy  
**Poster No:** 1  
**Abstract No:** 1011  
**Presenter:** Thomas B. Julian, MD  
**Location:**  
Display: Lakeside Center  
Level 4 E450b  
Discussion:  
5:00 p.m. - 6:00 p.m.  
North Building,  
Level 2 Hall B1  

**Monday, June 6, 2011**

**8:00 a.m. - 12:00 p.m.**  
**General Poster Session:**  
Tumor Biology  
**Poster No:** 30B  
**Abstract No:** 10590  
**Presenter:** Nathan R. Foster, MS  
**Location:**  
South Building,  
Level 3 Hall A  

**2:00 p.m. - 6:00 p.m.**  
**Poster Discussion Session:**  
Breast Cancer - Triple-negative/Cytotoxics/Local Therapy  
**Poster No:** 19  
**Abstract No:** 1029  
**Lead Author:** Kui Shen, PhD  
**Presenter:** Nan Song, PhD  
**Location:**  
Display: Lakeside Center  
Level 4 E450b  
Discussion:  
5:00 p.m. - 6:00 p.m.  
North Building,  
Level 2 Hall B1  

**25-hydroxy vitamin D and associated variables as predictors of breast cancer risk and tamoxifen benefit in NSABP P-1.**

**8:00 a.m. - 12:00 p.m.**  
**Trials in Progress Poster Session:**  
Clinical Trials  
**Poster No:** 36E  
**Abstract No:** TPS103  
**Presenter:** Wendy Parulekar, MD  
**Location:**  
South Building,  
Level 3, Hall A  

**Body mass index and DNA mismatch repair status in colon cancers from patients treated in adjuvant therapy trials.**

**8:00 a.m. - 12:00 p.m.**  
**Trials in Progress Poster Session:**  
Cancer Prevention/Epidemiology  
**Poster No:** 20  
**Abstract No:** 1528  
**Presenter:** Eitan Amir, MB, ChB  
**Location:**  
Display: South Building,  
Level 1 S102  
Discussion:  
11:30 a.m. - 12:30 p.m.  
South Building,  
Grand Ballroom 100a  

Early toxicity results with 3-D conformal external beam therapy from the NSABP B-39/RTOG 0413 accelerated partial breast irradiation trial.

Multigene predictors developed on breast cancer cell lines to predict patient chemotherapy response: A validation study on the NSABP B-27 trial.
Monday, June 6, 2011

10:15 a.m. - 10:45 a.m.
Best of ASCO Selection

Oral Abstract Presentation Session: Breast Cancer - Triple-negative/Cytotoxics/Local Therapy
Abstract No: LBA1005
Presenter: Harry D. Bear, MD, PhD
Location: North Building, Level 3 Hall B1
http://abstract.asco.org/AbstView_102_83942.html

Monday, June 6, 2011

1:00 p.m. - 5:00 p.m.
General Poster Session: Breast Cancer – HER2/ER
Poster No: 7F
Abstract No: 588
Presenter: Kalliopi P. Siziopikou, MD
Location: South Building, Level 3 Hall A
http://abstract.asco.org/AbstView_102_84489.html

1:00 p.m. - 5:00 p.m.
General Poster Session: Breast Cancer – HER2/ER
Poster No: 8B
Abstract No: 592
Presenter: Michael Crager, PhD
Location: South Building, Level 3 Hall A
http://abstract.asco.org/AbstView_102_78110.html

Monday, June 6, 2011

4:30 p.m. - 4:45 p.m.
Oral Abstract Presentation Session: Cancer Prevention/Epidemiology
Abstract No: 1505
Presenter: Stephanie R. Land, PhD
Location: South Building, Level 1, Grand Ballroom S100bc
http://abstract.asco.org/AbstView_102_83894.html

Cigarette smoking, fitness, and alcohol use as predictors of cancer outcomes among women in the National Surgical Adjuvant Breast and Bowel Project (NSABP) Breast Cancer Prevention Trial (BCPT).

Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

Using the 21-Gene Recurrence Score and the recently developed Recurrence Score-Pathologic-Clinical to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.

The effect on pCR of bevacizumab and/or antimetabolites added to standard neoadjuvant chemotherapy: NSABP protocol B-40.

Using the 21-Gene Recurrence Score and the recently developed Recurrence Score-Pathologic-Clinical to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.

Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.

Using the 21-Gene Recurrence Score and the recently developed Recurrence Score-Pathologic-Clinical to assess recurrence risk in patients with node-negative, ER-positive early-stage breast cancer receiving aromatase inhibitor treatment alone.

ASCO Electronic Publication-Only Abstract
A full-text version of the publish-only abstract will appear on www.asco.org and www.jco.org beginning May 18, 2011. It will not be presented during the meeting.

Publish-Only Abstract:
Abstract No: e21126
Lead Author: Frank A. Sinicrope, MD
NSABP Author: Gregory A. Yothers, PhD
http://abstract.asco.org/AbstView_102_83516.html

Body mass index as a prognostic and predictive factor in stage II/III colon cancer – an analysis of the ACCENT database.

Body mass index as a prognostic and predictive factor in stage II/III colon cancer – an analysis of the ACCENT database.